[A25-121] Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2026
Project no.:
A25-121
Commission:
Commission awarded on 25.09.2025 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Children and adolescents from 6 years of age with active enthesitis-associated arthritis and a body weight of at least 25 kg who have had an inadequate response to, or who are intolerant of, conventional therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
https://doi.org/10.60584/A25-121_en
| Project no. | Title | Status |
|---|---|---|
| A25-120 | Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-66 | Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-65 | Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-14 | Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |